Strategic Partnerships TVM Capital Life Science pursues a two-pronged strategy that includes Project-Focused Companies with a strategic relationship to Eli Lilly, indicating a strong appetite for co-development or collaboration with pharma players. Sales opportunities exist in partnering with portfolio companies seeking strategic alliances, licensing, or co-development funding.

Transatlantic Footprint With an international presence across North America and the EU and a portfolio targeting differentiated first-in-class assets, there is a clear opportunity to offer cross-border market access services, regulatory support, and regional funding programs to accelerate portfolio growth.

Early to Late Stage TVM invests across early-stage therapeutics through PFCs and late clinical-stage medical technologies, suggesting a need for a spectrum of services—from early-stage diligence and translational research support to late-stage clinical trial execution and commercialization planning.

Portfolio Growth Recent and ongoing financings for Vektor Medical and other ventures, plus partnerships like Tillotts, indicate an active deal flow and growth trajectory. There are opportunities to present add-on funding, secondary raises, or strategic exit planning to maximize return profiles.

Tech & Visibility The tech stack shows a modern online presence and marketing focus (WordPress, Shopify, SEO tooling). There is potential to offer premium digital marketing, investor relations automation, and portfolio company scale-up support to enhance fundraising and public visibility.